GGrantIndex
← Leaderboards

Beth Snitz

University Of Pittsburgh At Pittsburgh

$14,172,674
Attributed
$23,730,991
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.2M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,730,991 · 7

By mechanism

R37$14,337,476 · 1
P01$4,729,025 · 3
R01$3,349,839 · 1
P50$737,169 · 1
K23$577,482 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposS DiseaseParticipantCognitiveImageMild Cognitive ImpairmentDementiaSamplingAmyloid Beta-ProteinElderlyBrainBiological MarkersMemoryCognitionImpaired CognitionCohortPathologyMedicalNeuroimagingPositron-Emission TomographyBaseClinically RelevantFollow-UpReporting

Grant awards (28)

Mild Cognitive Impairment: A Prospective Community Study$2,671,320
R37 · FY2025 · AG
Mild Cognitive Impairment: A Prospective Community Study$2,938,462
R37 · FY2024 · AG
Clinical Core$1,212,154
P01 · FY2024 · AG · contact PI
Mild Cognitive Impairment: A Prospective Community Study$2,882,221
R37 · FY2023 · AG
Clinical Core$1,240,056
P01 · FY2023 · AG · contact PI
Mild Cognitive Impairment: A Prospective Community Study$2,906,516
R37 · FY2022 · AG
Clinical Core$1,301,466
P01 · FY2022 · AG · contact PI
Mild Cognitive Impairment: A Prospective Community Study$2,938,957
R37 · FY2021 · AG
Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study$676,713
R01 · FY2020 · AG · contact PI
Clinical Core$206,022
P01 · FY2020 · AG · contact PI
Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study$676,715
R01 · FY2019 · AG · contact PI
Clinical Core$210,856
P01 · FY2019 · AG · contact PI
Project 1: Amyloid Imaging in Subjective Cognitive Decline$143,787
P50 · FY2019 · AG · contact PI
Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study$673,715
R01 · FY2018 · AG · contact PI
Clinical Core$190,406
P01 · FY2018 · AG · contact PI
Project 1: Amyloid Imaging in Subjective Cognitive Decline$146,980
P50 · FY2018 · AG · contact PI
Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study$667,893
R01 · FY2017 · AG · contact PI
Clinical Core$178,121
P01 · FY2017 · AG · contact PI
Project 1: Amyloid Imaging in Subjective Cognitive Decline$150,173
P50 · FY2017 · AG · contact PI
Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study$654,803
R01 · FY2016 · AG · contact PI
Clinical Core$189,944
P01 · FY2016 · AG · contact PI
Project 1: Amyloid Imaging in Subjective Cognitive Decline$150,173
P50 · FY2016 · AG · contact PI
Project 1: Amyloid Imaging in Subjective Cognitive Decline$146,056
P50 · FY2015 · AG · contact PI
Cognitive Complaints and Decline and B-Amyloid Deposition in Non-Demented Elderly$135,872
K23 · FY2014 · AG · contact PI
Cognitive Complaints and Decline and B-Amyloid Deposition in Non-Demented Elderly$135,872
K23 · FY2013 · AG · contact PI
Cognitive Complaints and Decline and B-Amyloid Deposition in Non-Demented Elderly$100,825
K23 · FY2012 · AG · contact PI
Subjective Cognitive Complants, Cognitive Decline and B-Amyloid Deposition in Non$100,825
K23 · FY2011 · AG · contact PI
Subjective Cognitive Complants, Cognitive Decline and B-Amyloid Deposition in Non$104,088
K23 · FY2010 · AG · contact PI